Orthofix wins Medicare reimbursement restoration for bone growth stimulators

CMS issued revised guidance on July 1, 2026, withdrawing billing changes it had implemented on May 18 for non-invasive bone growth stimulators (HCPCS codes E0747, E0748, E0760). The May changes had followed an FDA reclassification of these devices from Class III to Class II in April, which triggered CMS to modify billing requirements and fee schedules. The reversal restores the prior Medicare payment treatment retroactively to May 18.

For Orthofix, this means Medicare reimbursement rates for its bone growth stimulator products will return to pre-May 18 levels, reversing what were presumably lower rates that had been in effect for about six weeks. The company's bone growth stimulator business now operates under the same Medicare payment structure it had before the brief May-July disruption. The guidance directs that devices furnished on or after May 18 be paid under the prior treatment, so the retroactivity covers the interim period, though the filing does not address how already-processed claims will be handled.